Inclusion Criteria:  Histologically-confirmed esophageal squamous cell carcinoma and whose tissue samples were taken before treatment; Tumors of the esophagus are located in the thoracic cavity; Pre-treatment stage as cT1b-3N1-2M0 or cT3-4aN0M0(AJCC/UICC 8th Edition) Age is between 18 years and 75 years; Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and expected survival time ≥12 months; Adequate cardiac function. All patients should perform ECG, and those with a cardiac history or ECG abnormality should perform echocardiography with the left ventricular ejection fraction > 50 %; Adequate respiratory function with FEV1≥1.2L, FEV1%≥50% and DLCO≥50% shown in pulmonary function tests ; Adequate bone marrow function (White Blood Cells >4x10^9 /L; Neutrophil >2.0×10^9 /L; Hemoglobin > 90 g/L; platelets>100x10^9 /L); Adequate liver function (Total bilirubin <1.5x Upper Level of Normal (ULN); Aspartate transaminase(AST) and Alanine transaminase (ALT) <1.5x ULN); Adequate renal function (Glomerular filtration rate (CCr) >60 ml/min; serum creatinine (SCr) ≤120 µmol/L); The patient has provided written informed consent and is able to understand and comply with the study;  Exclusion Criteria:  Exclusion Criteria associated with Cancer:  Patients with histological non-squamous cell carcinoma; Patients with advanced non-operable or metastatic esophageal cancer; Pre-treatment stage as cM+, cN3 or cT4b(non-curatively-resectable verified by the local surgical investigator, AJCC/UICC 8th Edition) or cTis-1a, cT1bN0; Patients with another previous or current malignant disease which is likely to interfere with treatment or the assessment of response in the judgement of the local surgical investigator;  Patients who have received or are receiving other chemotherapy, radiotherapy or targeted therapy;  Other Exclusion Criteria:  Patients with autoimmune diseases history; Recently or currently taking Glucocorticoids or Immunosuppressants; Patients who underwent immunotherapy in the past; Allergy to any antibody drugs or allergy to Paclitaxel and Carboplatin. Past or currently suffering from chronic or recurrent autoimmune diseases; Patients with active infection of immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); HIV seropositivity; HBV DNA or HCV RNA positive; Patients with organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation); Patients with severe systematic intercurrent disease, such as active infection or poorly controlled diabetes; coagulation disorders; hemorrhagic tendency or under treatment of thrombolysis or anticoagulant therapy; Any patient with a significant medical condition which is thought unlikely to tolerate the therapies. Such as cardiac disease (e.g. symptomatic coronary artery disease or myocardial infarction within last 12 months), clinically-significant lung disease, clinically-significant bone marrow, liver, renal function disorder; Pregnant or lactating women and fertile women who will not be using contraception during the trial; Participation in another intervention clinical trial with interference to the chemotherapeutic or chemoradiotherapeutic intervention during this study or during the last 30 days prior to informed consent; Expected lack of compliance with the protocol.